Printer Friendly

Mylan Inc unveils generic FDA approved Amidate Injection for general anesthesia.

M2 EQUITYBITES-August 7, 2012-Mylan Inc unveils generic FDA approved Amidate Injection for general anesthesia(C)2012 M2 COMMUNICATIONS

Generic pharmaceuticals company Mylan Inc (NasdaqGS:MYL) reported on Monday the receipt of final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Etomidate Injection USP, 2 mg/mL packaged in 40 mg/20 mL single-use vials.

This FDA approval was awarded to the company's business, Mylan Institutional.

Effective immediately, Mylan has commenced shipping the Etomidate Injection 20 mL vial in packs of ten.

The company's Etomidate Injection USP is the generic version of Hospira's Amidate Injection, which is indicated by intravenous injection for the induction of general anesthesia.

According to IMS Health, Etomidate Injection USP, 2 mg/mL, packaged in 20 mL vials, had recorded US sales of about USD6.58m for the 12 months ending 31 March 2012.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 7, 2012
Previous Article:Mitsubishi Electric announces order receipt for high-speed elevators in two Chengdu buildings.
Next Article:-Goldman Sachs to help Duff & Phelps issue shares.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters